centuri
discoveri
abo
blood
group
bg
karl
landstein
current
differ
bg
system
recogn
bg
antigen
defin
intern
societi
blood
transfus
isbt
recent
overview
provid
societi
websit
differ
bg
antigen
evolv
genet
polymorph
red
blood
cell
rbc
surfac
molecul
peptid
carbohydr
abo
antigen
howev
bg
antigen
includ
abo
express
rbc
also
present
mani
tissu
therefor
histobg
antigen
appear
relev
transfus
medicin
also
transplant
moreov
histobg
antigen
may
also
occur
glandular
secret
exampl
abo
lewi
antigen
found
saliva
mucin
free
oligosaccharid
found
milk
urin
structur
particular
histobg
glycan
defin
sugar
assembl
sugar
free
form
attach
anoth
molecul
glycan
gener
known
directli
involv
pathophysiolog
everi
major
diseas
conclud
knowledg
glycosci
need
realiz
goal
person
medicin
take
advantag
substanti
invest
human
genom
proteom
research
impact
human
health
state
recent
report
us
nation
academi
although
lack
express
bg
antigen
directli
result
diseas
known
far
presenc
absenc
certain
bg
antigen
rbc
surfac
tissu
bodili
fluid
found
associ
suscept
variou
diseas
beyond
recogn
role
incompat
reaction
transfus
transplant
pregnanc
largest
bodi
evid
carbohydratebas
histobg
abo
lewi
le
secretor
se
avail
particularli
context
infecti
diseas
cancer
review
nevertheless
histobg
glycan
far
exploit
diagnost
therapeut
applic
apart
promin
except
cancer
antigen
ca
ie
sialyl
glycanbas
bg
ie
abo
le
h
se
ii
globosid
glob
forssman
for
highincid
antigen
sd
altogeth
repres
distinct
antigen
structur
overview
glycanbas
bg
system
associ
rbc
phenotyp
distribut
among
popul
given
tabl
review
potenti
use
glycanbas
histobg
context
tabl
glycan
histoblood
group
bg
respons
gene
blood
type
distribut
among
popul
gsl
lke
lke
almost
person
medicin
discuss
well
technolog
suitabl
determin
research
well
clinic
set
glycan
histobg
antigen
occur
variou
type
glycoconjug
ie
glycosphingolipid
gsl
nand
oglycan
cell
membranebound
secret
glycoprotein
mucin
free
oligosaccharid
milk
urin
tabl
fig
exampl
abo
activ
erythrocyt
found
origin
glycoprotein
polyglycosylceramid
glycoconjug
even
regard
glycan
portion
divers
precursor
oligosaccharid
togeth
variou
antigen
determin
potenti
overal
structur
divers
histobgact
compound
instanc
abo
determin
found
type
chain
noglycan
attach
protein
neo
lactoseri
gsl
fig
b
furthermor
decor
olink
type
chain
mucin
structur
ident
socal
antigen
fig
type
chain
bear
abo
epitop
part
globoand
ganglioseri
gsl
fig
fig
comprehens
review
express
histobg
antigen
precursor
tissuespecif
associ
embryolog
origin
tissu
degre
differenti
respect
cell
within
tissu
follow
minim
structur
featur
glycan
histobg
epitop
briefli
describ
summari
relev
gene
enzym
name
product
given
tabl
extens
overview
genet
biochem
epidemiolog
histor
aspect
reader
refer
literatur
ii
epitop
base
repeat
unit
either
linear
nacetyllactosamin
chain
fig
name
blood
group
emerg
abbrevi
individu
thu
repres
upper
lowercas
letter
structur
ubiquit
express
except
rare
adult
phenotyp
lack
branch
structur
either
erythrocyt
even
tissuewid
depend
type
mutat
similar
polylactosamin
ii
structur
substrat
variou
glycosyltransferas
includ
sialyltransferas
abo
le
bg
transferas
describ
follow
review
see
ref
biosynthesi
antigen
abo
le
histobg
close
relat
although
respons
glycosyltransferas
express
sever
independ
gene
abo
gene
chromosom
hgene
segen
legen
chromosom
abbrevi
well
full
name
includ
linkag
specif
respons
gene
fucosyltransferas
fut
see
tabl
start
type
lactosamin
residu
lefut
sefut
compet
gener
le
type
epitop
le
respect
fig
type
se
antigen
substrat
abo
geneencod
b
transferas
produc
b
antigen
one
activ
allel
present
furthermor
type
fucosyl
lefut
gener
le
b
epitop
le
le
b
structur
modifi
wherea
b
antigen
substrat
lefut
result
ale
b
ble
b
antigen
pathway
take
place
secretori
tissu
cell
erythrocyt
sinc
type
structur
highli
express
outer
epitheli
layer
higher
degre
differenti
eg
oral
gut
mucosa
substrat
sefut
sefut
activ
caucasian
socal
secretor
tabl
le
gene
inact
precursor
structur
le
c
type
precursor
le
type
classifi
part
bg
collect
found
plasma
red
blood
cell
nonsecretor
secretor
respect
erythrocyt
normal
sefut
lefut
express
bear
abo
antigen
mainli
type
chain
prefer
substrat
hfut
type
structur
le
x
antigen
subtermin
glcnac
gener
either
ledepend
one
fig
addit
sefut
express
respect
cell
type
h
generegul
hfut
primarili
synthes
type
structur
modifi
b
transferas
incl
action
type
fut
result
le
epitop
ie
type
isom
le
b
analog
abovedescrib
pathway
fig
exampl
human
histoblood
group
glycan
carrier
cell
surfac
bodi
fluid
histoblood
group
glycan
decor
variou
core
glycan
attach
lipid
black
wave
protein
blue
line
anchor
cell
membran
secret
glycoproteinsmucin
free
oligosaccharid
found
larg
quantiti
human
milk
blood
group
antigen
found
nand
oglycan
protein
microbi
receptor
recogn
variou
histoblood
group
antigen
therebi
attach
host
epitheli
surfac
altern
solubl
glycan
serv
decoy
receptor
pathogen
type
chain
type
ale
ble
largest
end
product
respect
glycosyltransferas
express
activ
form
termin
le
b
le
aor
bepitop
usual
modifi
elong
branch
appli
subtermin
le
le
x
antigen
for
glob
bg
relat
collect
gsl
review
classif
antigen
chang
sever
time
past
current
state
accord
isbt
list
tabl
structur
gsl
compos
lipophil
part
contain
long
chain
fatti
acid
sphingosin
anchor
plasma
membran
hydrophil
glycan
head
group
fig
start
lactosylceramid
either
pk
antigen
globotriaosylceramid
synthes
via
action
geneencod
galactosyltransferas
lead
globoseri
gsl
pathway
antigen
synthes
via
action
enzym
follow
two
nonbgrel
glycosyltransferas
gener
neolactoseri
gsl
fig
p
antigen
product
activ
requir
structur
globoand
neo
lactoseri
gsl
act
precursor
gslattach
abo
le
hse
epitop
indic
fig
nullallel
either
appar
rare
case
globogsl
produc
furthermor
rare
variant
enzym
link
express
antigen
antigen
found
individu
activ
gbgt
gene
normal
activ
human
nonprim
anim
except
antigen
rbcspecif
express
relat
antigen
common
mani
tissu
cell
type
express
level
vari
cell
cycl
differenti
addit
blood
group
system
collect
classifi
isbt
two
glycan
histobg
mention
ie
high
incid
antigen
sd
ttn
system
tn
antigen
part
olink
mucintyp
glycan
primarili
substrat
tsynthas
ubiquit
express
respons
antigen
oglycan
core
format
review
see
ref
antigen
furthermor
ident
type
chain
elong
andor
decor
bg
antigen
fig
sd
antigen
includ
high
incid
seri
accord
isbt
classif
due
high
preval
caucasian
similar
discrep
erythrocyt
vs
secret
phenotyp
le
bg
individu
rbc
sd
phenotyp
may
still
display
sd
antigen
secret
especi
urin
review
see
ref
minim
antigen
structur
shown
fig
share
sd
cad
antigen
assum
product
geneencod
howev
latter
result
activ
enzym
variant
consequ
sd
individu
sd
structur
primarili
nlink
glycan
wherea
cadindividu
also
express
type
olink
glycan
longchain
sialylparaglobosid
genet
determin
repertoir
glycosyltransferas
basi
individu
histobg
phenotyp
howev
genet
divers
allel
found
abo
locu
allel
h
se
le
loci
togeth
zygos
give
rise
enorm
variat
level
antigen
express
includ
weak
phenotyp
lead
blood
group
discrep
moreov
pregnant
women
individu
differ
hematolog
disord
especi
newborn
weak
express
histobg
antigen
rbc
report
agedepend
abo
antigen
express
rbc
connect
express
antigen
major
precursor
abo
structur
rbc
antigen
express
rbc
neglig
birth
reach
full
adult
level
age
month
give
exampl
oncodevelopment
natur
histobg
antigen
express
express
level
abos
le
antigen
also
vari
tremend
within
adult
individu
time
regulatori
mechan
histobgrel
glycogen
express
microrna
transcript
factor
express
studi
vast
variabl
actual
histobg
phenotyp
furthermor
deriv
numer
interrel
respect
biosynthet
pathway
demonstr
close
relationship
abos
le
bg
well
glob
for
addit
precursor
chain
ii
ttn
fig
anoth
import
modif
howev
directli
relat
blood
group
termin
galactos
prior
action
fut
type
chain
produc
sialyl
sialyl
x
antigen
respect
fig
combin
histobg
antigen
recogn
role
context
cancer
discuss
interestingli
sialyltransferas
also
compet
fut
substrat
tabl
structur
shown
carri
betalink
ceramid
residu
reduc
end
glucos
depict
simplic
reason
link
synthesi
pathway
gslbase
blood
group
antigen
abo
le
hse
group
also
shown
gray
box
solid
line
repres
common
pathway
accord
common
glycosyltransferas
gene
allel
wherea
dash
line
symbol
rare
one
modifi
ref
therefor
impact
express
level
interconnect
abo
le
glycan
bg
antigen
differ
level
substrat
specif
addit
impact
overal
complex
biosynthet
network
histobg
glycosyltransferas
antigen
synthes
one
enzym
see
hse
instanc
enzym
limit
one
type
acceptor
see
chain
type
sefut
variou
substrat
lefut
one
type
linkag
lefut
act
taken
togeth
variou
factor
impact
final
phenotyp
ie
presenc
individu
histobg
glycan
cell
surfac
bodi
fluid
obvious
variou
associ
found
bg
glycan
differ
diseas
diseas
stage
healthpromot
factor
make
histobg
glycan
intrigu
topic
field
person
medicin
discuss
follow
paragraph
tabl
major
conclus
select
epidemiolog
studi
report
associ
differ
diseas
abo
le
se
histobg
summar
common
rare
bg
phenotyp
rbc
direct
caus
relationship
known
bg
nullallel
inherit
diseas
sinc
glycan
known
predomin
role
recognit
molecul
particular
infect
associ
glycan
histobg
polymorph
variou
infecti
diseas
surpris
mani
vertebr
speci
maintain
function
ab
gene
howev
human
roughli
half
popul
genotyp
result
nonfunct
ab
enzym
abo
polymorph
link
evolutionari
adapt
defens
interand
intraspeci
infect
sinc
individu
produc
antibodi
nonself
ab
antigen
exposur
antigen
origin
eg
pathogen
mask
pathogen
adhes
glycotop
glycan
anoth
defens
mechan
suggest
wherea
microbi
attach
site
epitheli
surfac
support
colon
histobg
antigen
solubl
glycan
mucin
free
oligosaccharid
human
milk
may
serv
decoy
receptor
pathogen
defens
fig
glycan
epitop
includ
histobg
import
role
hostpathogen
interact
sinc
glycan
act
recognit
site
bacteri
adhesin
secondli
pathogen
express
surfac
epitop
mimic
host
evad
immun
respons
propos
helicobact
pylori
le
antigen
remark
h
pylori
abl
bind
antigen
structur
host
epitheli
surfac
h
pylori
present
half
world
popul
chronic
infect
link
gastriti
peptic
ulcer
gastric
cancer
high
degre
heterogen
diseas
phenotyp
bacterium
abl
attach
le
b
antigen
without
addit
b
epitop
therefor
propos
link
bg
howev
clinic
data
associ
h
pylori
gastric
cancer
abol
bg
contradictori
tabl
higher
incid
h
pylori
lower
incid
aindividu
report
multipl
studi
strikingli
gastric
cancer
risk
higher
bg
incid
rate
ratio
ci
wherea
peptic
ulcer
risk
found
higher
oindividu
larg
populationbas
studi
link
le
se
phenotyp
seem
even
unclear
instanc
se
statu
h
pylori
infect
shown
independ
risk
factor
gastric
diseas
higher
risk
nons
although
le
b
se
seem
play
crucial
role
h
pylori
adhes
tissu
level
h
pylori
infect
patient
gastric
ulcer
shown
increas
le
loss
h
le
b
express
inflam
gastric
mucosa
author
claim
abo
le
antigen
good
indic
cellular
alter
gastric
epithelium
leand
seposit
women
found
lower
risk
urinari
tract
infect
compar
leneg
nons
sinc
adhesin
uropathogen
escherichia
coli
recogn
variou
globoseri
gsl
includ
p
especi
sialyl
lke
antigen
vitro
mask
function
antigen
compet
sialyl
secretor
ie
le
b
ab
propos
b
ab
individu
pediatr
cohort
found
suscept
salmonellosi
variou
e
coli
type
infect
mening
sepsi
pyelonephr
compar
individu
contrast
shigella
infect
preval
individu
relat
higher
suscept
oindividu
infect
anoth
shigatoxin
relat
bacteri
strain
ie
e
coli
studi
found
pneg
individu
like
develop
sever
hemolyt
urem
syndrom
infect
possibl
due
higher
induct
tnfalpha
pk
lke
histobg
antigen
associ
shiga
toxinand
verotoxinproduc
e
coli
strain
stec
ehec
moreov
pkknockout
mice
show
reaction
verotoxin
administr
wherea
basal
level
pk
express
alreadi
lethal
wildtyp
mice
shigaand
verotoxinbind
pk
antigen
found
human
milk
may
act
decoy
receptor
breastf
infant
lower
risk
diarrheal
diseas
compar
formulaf
one
level
seposit
free
oligosaccharid
human
milk
also
posit
correl
eg
protect
e
coliinduc
diarrhea
breastf
infant
similarli
oligosaccharid
human
milk
associ
protect
campylobact
jejuni
diarrhea
possibl
due
function
decoy
receptor
prematur
infant
nonor
lows
phenotyp
well
genotyp
furthermor
associ
sever
outcom
necrot
enterocol
gramneg
sepsi
express
ab
antigen
epithelia
secret
case
seposit
individu
might
furthermor
protect
pneumonia
caus
streptococci
pathogen
secret
glycosidas
act
type
chain
b
le
structur
known
virul
factor
secretor
predominantli
express
type
chain
shield
b
epitop
might
therefor
protect
pathogen
adhes
nonsecretor
also
report
suscept
infect
caus
neisseria
meningitidi
haemophilu
influenza
se
le
ab
bg
seem
also
play
role
vibrio
cholera
infect
diseas
sever
pk
p
abh
antigen
latter
two
milk
oligosaccharid
gener
seand
lefucosyltransferas
respect
may
play
role
pseudomona
aeruginosa
adhes
pk
antigen
also
bind
adhesin
p
streptococcu
sui
pig
pathogen
caus
mening
human
variou
studi
demonstr
stimul
antibodi
titer
bg
antigen
differ
condit
bacteri
exposur
thu
support
hypothesi
immunolog
defens
function
bg
antigen
non
express
anoth
indic
implic
abo
histobg
immunolog
process
given
find
efficaci
vibriocid
antibodi
respons
cholera
vaccin
lower
bg
compar
bg
individu
therefor
explor
role
antibg
antibodi
respons
protect
follow
specif
vaccin
great
interest
shown
system
biolog
approach
use
glycan
microarray
analysi
immunoglobulin
g
prepar
differ
healthi
popul
pool
antibodi
prepar
bound
variou
selfantigen
ligand
includ
especi
glob
le
bg
bg
b
epitop
also
sialyl
case
author
suggest
protect
role
selfantibodi
block
bacteri
attach
site
releas
epitheli
surfac
context
viral
infect
associ
nonb
well
se
genotyp
phenotyp
noroviru
rotaviru
infect
gastroenter
report
numer
studi
tabl
addit
certain
rotaviru
genotyp
p
mainli
infect
neonat
found
attach
specif
saliva
neonat
infant
adult
due
high
express
polylactosamin
ie
antigen
differ
viral
protein
select
rotavir
genotyp
found
bind
either
epitop
type
isom
without
intern
le
x
human
milk
oligosaccharid
strainand
viral
proteindepend
manner
consequ
infect
seem
highli
depend
viru
genotyp
interact
host
ancestryethn
differ
histobg
noroviru
multival
viruslik
particl
vaccin
therefor
propos
repres
broad
set
viral
genotyp
strain
interestingli
antihistobg
immunoglobulin
g
total
antibodi
titer
prior
challeng
noroviru
posit
correl
protect
infect
placeborecipi
vaccine
frequenc
sever
diseas
lower
higher
prechalleng
antihistobg
antibodi
titer
develop
effici
vaccin
noroviru
rotaviru
individu
approach
address
relev
factor
viru
genotyp
specif
particl
adjuv
use
vaccin
interact
histobg
antigen
antihistobg
antibodi
recipi
particular
interest
futur
obg
associ
resist
toward
sever
acut
respiratori
syndrom
caus
coronaviru
se
phenotyp
link
respiratori
viru
diseas
includ
influenza
rhinoviru
respiratori
syncyti
viru
echoviru
nonsecretor
genotyp
phenotyp
also
associ
protect
aspect
hiv
reduc
infect
risk
p
slower
diseas
progress
p
b
likewis
pk
express
shown
protect
infect
vitro
compar
p
phenotyp
role
bg
hiv
infect
review
ref
contrast
p
antigen
might
implic
parvoviru
infect
shown
primari
receptor
bg
also
associ
parasit
diseas
tabl
particular
bgo
recogn
genet
factor
lower
risk
sever
malaria
high
percentag
oindividu
malariaendem
region
support
hypothesi
select
advantag
bg
furthermor
incid
schistosom
infect
diseas
sever
link
abg
sinc
histobg
glycan
recogn
role
oncodevelopment
antigen
moreov
link
tissu
differenti
stage
surpris
chang
express
context
malign
describ
recent
glycosyl
chang
cancer
extens
review
see
ref
moreov
epidemiolog
studi
found
decreas
risk
variou
type
cancer
bg
increas
risk
bg
found
metaanalysi
tabl
howev
anoth
metaanalysi
signific
associ
found
compar
vs
nono
bg
except
exocrin
pancreat
cancer
ci
bgo
vs
nono
associ
found
le
se
genotyp
breast
cancer
suscept
axillari
lymph
node
metastasi
respect
clinic
sampl
increas
either
incompletetrunc
precursor
structur
tn
pk
h
ii
type
chain
de
novo
express
cancer
antigen
ie
increas
sialyl
ax
fig
p
le
b
se
antigen
otherwis
nullallel
individu
observ
variou
cancer
type
depend
cancer
stage
accordingli
sialyltn
recogn
tumor
marker
propos
target
design
anticanc
vaccin
howev
limit
success
date
sialyl
ax
appear
play
role
later
tumor
stage
especi
metastasi
notabl
le
transcript
sialyl
ax
antigen
express
shown
upregul
h
pylori
infect
patient
earli
onset
gastric
carcinoma
moreov
sialyl
elev
variou
type
gastrointestin
carcinoma
approv
prognost
marker
pancreat
cancer
therapi
howev
leposit
patient
sinc
leneg
individu
express
activ
sialyl
serum
level
significantli
lower
even
nondetect
pancreat
cancer
patient
nullallel
legen
anoth
signific
glycom
bg
antigen
chang
cancer
loss
b
antigen
premalign
malign
metastat
tissu
otherwis
aor
bposit
individu
switch
furthermor
link
enhanc
cellular
motil
poor
prognosi
ab
express
loss
goe
along
higher
abund
precursor
structur
antigen
carcinoma
secretor
wherea
cancer
tissu
nonsecretor
experi
lower
antigen
express
moreov
increas
distribut
h
antigen
throughout
layer
malign
tissu
compar
restrict
pattern
normal
mucosa
found
analog
activ
seand
hgene
encod
enzym
higher
rectal
carcinoma
normal
tissu
interestingli
sehantigen
found
cecal
tumor
sea
well
nons
patient
absent
normal
tissu
nonsecretor
recent
investig
cyst
fluid
tissu
ovarian
tumor
shown
remark
differ
abo
bg
antigen
express
differ
tumor
stage
subtyp
use
mass
spectrometri
averag
composit
fucosyl
abo
le
antigen
sialyl
mucintyp
glycan
author
abl
distinguish
three
group
sampl
lowgrad
low
malign
potenti
carcinoma
benign
mucin
ii
serou
epitheli
ovarian
carcinoma
iii
serou
benign
sampl
nonsecretor
sampl
except
due
genet
determin
lower
express
bg
epitop
epithelia
describ
glycom
chang
cancer
potenti
therapeut
vaccin
target
includ
histobg
antigen
moreov
abo
bg
demonstr
possibl
paramet
detect
respond
therapeut
prostat
cancer
vaccin
compar
bg
aab
particip
bg
b
patient
experienc
enhanc
surviv
vaccin
especi
develop
antibodi
respons
antigen
explain
author
presenc
poxvir
vector
use
vaccin
show
structur
similar
aantigen
verifi
conclus
drawn
similar
studi
could
open
invalu
opportun
effect
immun
strategi
bloodgroup
specif
manner
design
vaccin
bg
epitop
complementari
bg
recipi
would
therebi
develop
enhanc
immun
respons
summari
malignancyassoci
chang
histobg
glycan
differ
individu
differ
genet
histobg
background
may
even
tumor
stageand
subtypespecif
reveal
promis
biomark
earli
cancer
diagnost
vaccin
target
relev
factor
includ
person
oncotherapeut
approach
associ
abo
especi
nons
phenotyp
genotyp
inflammatori
autoimmun
diseas
crohn
diseas
primari
scleros
cholang
chronic
pancreat
type
diabet
report
addit
childhood
asthma
found
higher
incid
secretor
bg
andor
leneg
phenotyp
possibl
explan
higher
suscept
crohn
diseas
nonsecretor
link
via
gut
microbiota
intestin
microbiom
composit
differ
healthi
se
nons
individu
well
differ
abo
phenotyp
among
secretor
moreov
perturb
gut
microbiota
metabol
factor
hostmicrobi
environ
nonsecretor
heterozyg
individu
crohn
diseas
report
fucosyl
gut
primarili
mediat
induc
certain
gut
bacteria
via
yet
unknown
mechan
central
role
hostmicrob
symbiosi
suppress
pathogen
interestingli
host
fucos
util
specif
microb
downregul
nons
mice
fed
glucoserich
polysaccharidedefici
diet
demonstr
intens
interact
host
genet
diet
gut
microbiom
notabl
gastrointestin
malign
particular
colorect
cancer
also
link
gut
microbiota
composit
intriguingli
previous
unrecogn
regulatori
role
histobg
antigen
inflammatori
adhes
process
propos
due
strong
correl
abo
locu
plasma
concentr
solubl
intercellular
adhes
molecul
moreov
abo
locu
associ
diabet
type
eselectin
level
besid
level
addit
lower
risk
cardiovascular
associ
diseas
found
bg
individu
link
bg
antigen
platelet
glycoconjug
recent
review
interestingli
bg
individu
lower
level
blood
clot
factor
von
willebrand
fviii
due
shorter
plasma
halflif
addit
cancerrel
chang
ii
antigen
express
mention
rare
diseas
associ
report
adult
phenotyp
correl
found
congenit
cataract
certain
kindr
put
explain
direct
effect
lack
branch
type
polylactosamin
result
certain
nullallel
gene
variant
iantigen
produc
enzym
human
len
epitheli
cell
indic
exist
variant
tsynthas
gene
gener
antigen
associ
suscept
iga
nephropathi
downregul
gene
result
strong
reduct
sd
antigen
express
colon
concomit
increas
sialyl
x
express
observ
colon
cancer
might
offer
promis
opportun
cancer
therapi
futur
defin
us
food
drug
administr
person
medicin
tailor
medic
treatment
individu
characterist
need
prefer
patient
stage
care
includ
prevent
diagnosi
treatment
followup
briefli
demonstr
exampl
interact
individu
se
statu
gut
microbiota
histobg
might
play
signific
role
alreadi
earli
stage
diseas
prevent
anoth
exampl
variou
histobg
glycan
human
milk
suggest
provid
doubl
protect
breastf
child
via
prebiot
antimicrobi
activ
gut
decoy
function
milk
glycan
particular
highli
abund
free
oligosaccharid
mucin
glycan
offer
yet
underexamin
possibl
novel
prevent
therapeut
antibiot
strategi
emerg
highthroughput
analyt
technolog
glycan
microarray
multiplex
capillari
electrophoresi
matrixassist
laser
desorptionion
maldi
mass
spectrometri
ms
pave
way
discoveri
novel
bioactiv
compound
tradit
bg
phenotyp
perform
via
target
immunolog
assay
use
antisera
lectin
monoclon
antibodi
without
stain
bodi
fluid
tissu
determin
specif
antigen
immunoassay
also
use
determin
sialyl
level
clinic
genotyp
glycosyltransferas
transcript
analysi
well
standard
proteom
techniqu
current
increasingli
use
also
context
bgtype
therefor
compli
requir
modern
person
medicin
furthermor
might
use
patient
stratif
set
genet
histobg
background
combin
natur
antibg
antigen
antibodi
play
role
vaccin
efficaci
studi
revers
abotyp
method
develop
muthana
colleagu
use
serum
glycan
array
proven
particularli
use
sinc
enabl
retrospect
bg
type
without
whole
blood
sampl
avail
current
knowledg
signific
histobg
context
diseas
summar
section
thu
far
mainli
base
observ
studi
stratifi
patient
control
blood
type
show
associ
diseas
diseas
stage
tabl
inform
underli
mechan
limit
date
possibl
due
extrem
reductionist
approach
emerg
transfus
medicin
ie
group
individu
categori
deduc
serolog
phenotyp
tabl
howev
knowledg
patient
rbc
glycosyltransferas
express
indic
final
complex
glycom
profil
especi
take
account
vast
tissueand
diseasespecif
variat
histobg
antigen
precursor
conjug
well
interact
differ
bg
discuss
section
thu
simultan
map
glycan
differ
histobg
next
inform
carrier
would
provid
increas
degre
comprehens
requir
investig
mechan
behind
bgtodiseas
associ
present
modern
glycoanalyt
techniqu
ms
liquid
chromatographi
principl
capabl
provid
type
inform
multipl
level
semi
quantit
determin
termin
glycosyl
includ
histobg
glycan
well
sialyl
level
appear
interrel
map
overal
glycom
furthermor
provid
inform
core
glycan
structur
bear
termin
bg
glycan
ie
oglycan
glycan
portion
gslbase
bg
structur
determin
proteinpeptid
lipid
carrier
thu
instead
assign
sampl
limit
set
categori
base
tradit
genet
bg
type
advanc
glycoanalyt
enabl
unpreced
insight
vast
complex
varieti
structur
fig
reflect
underli
complex
biolog
process
therefor
glycom
togeth
glycoproteom
glycolipidom
technolog
refin
allow
unambigu
isomerspecif
structur
character
optim
quantit
histobg
glycan
high
potenti
diagnost
prognost
biomark
context
infecti
noncommunic
diseas
current
appli
glycoanalyt
techniqu
field
biomark
discoveri
cancer
tissu
present
ref
major
progress
glycom
approach
distinguish
linkag
andor
differ
monosaccharid
speci
made
recent
field
nand
oglycom
howev
glycom
histobg
neglect
last
year
except
rather
target
approach
recent
studi
tradit
target
techniqu
combin
liquidchromatographym
ms
success
appli
show
great
potenti
mucintyp
histobg
glycan
ovarian
tumor
stage
classif
tissu
also
cystic
fluid
glycom
approach
minut
amount
prefer
noninvas
acquir
patient
sampl
saliva
tear
milk
urin
fece
particular
use
context
earli
diagnosi
populationwid
screen
discoveri
novel
function
histobg
appli
highend
technolog
warrant
interestingli
spatial
organ
abo
antigen
patch
rbc
b
individu
shown
differ
bgspecif
manner
result
higher
lower
bind
sialic
acidbind
protein
siglec
sialic
acidrich
cluster
coexpress
nearbi
abh
region
author
claim
found
novel
function
abh
antigen
ie
indirect
stabil
glycanprotein
interact
research
warrant
reveal
function
relev
multicompound
complex
involv
concert
bind
glycan
multival
manner
final
combin
differ
omic
techniqu
includ
glycom
like
enhanc
perform
diagnost
prognost
approach
pave
way
success
translat
clinic
first
exampl
pioneer
combin
genomicsglycom
studi
potenti
epigenet
regulatori
factor
lefut
next
fut
propos
basi
plasma
protein
nglycom
studi
combin
genom
proteom
metabolom
glycom
data
contain
histobg
antigen
inform
differ
bodi
fluid
andor
tissu
could
help
reveal
mechan
behind
describ
diseas
associ
may
provid
improv
diseas
biomark
well
therapeut
target
futur
author
declar
conflict
interest
transpar
document
associ
articl
found
onlin
version
